Does short-term treatment with ularitide improve clinical outcomes or reduce long-term cardiovascular mortality in patients with acute heart failure?
Short-term treatment with ularitide in acute heart failure provides favorable physiological effects but fails to improve clinical composite endpoints or long-term cardiovascular mortality.
In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634 .).
Packer et al. (Wed,) studied this question.